Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist

AAPS Journal

Volumn 14, Issue 1, 2012, Pages 68-78

  Bruderer, Shirin ^a   Äänismaa, Päivi ^a   Homery, Marie Claude ^b   Häusler, Stephanie ^a   Landskroner, Kyle ^a   Sidharta, Patricia N ^a   Treiber, Alexander ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Biotrial   (France)

Author keywords

cyclosporine (Cs); endothelin; macitentan; pharmacokinetics; rifampin

Indexed keywords

ACT 132577; ACT 373898; CYCLOSPORIN A; ENDOTHELIN RECEPTOR ANTAGONIST; MACITENTAN; ORGANIC ANION TRANSPORTER 2; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CHO CELL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; LOADING DRUG DOSE; MALE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; STEADY STATE; UPREGULATION;

ADULT; ANIMALS; AREA UNDER CURVE; CHO CELLS; CRICETINAE; CRICETULUS; CROSS-OVER STUDIES; CYCLOSPORINE; DRUG INTERACTIONS; HUMANS; MALE; ORGANIC ANION TRANSPORTERS; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RIFAMPIN; SULFONAMIDES; YOUNG ADULT;

EID: 84857627857     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9316-3     Document Type: Article

References (29)

1. M Iglarz C Binkert K Morrison W Fischli J Gatfield A Treiber, et al. 2008 Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist J Pharmacol Exp Ther 327 3 736 45 18780830 10.1124/jpet.108.142976 1:CAS:528:DC%2BD1cXhsVCjtLvO
2. PN Sidharta PL van Giersbergen A Halabi J Dingemanse 2011 Macitentan: entry-into-humans study with a new endothelin receptor antagonist Eur J Clin Pharmacol 67 10 977 984 21541781 10.1007/s00228-011-1043-2 1:CAS:528: DC%2BC3MXhtFKiu7zL
3. S Bruderer P Sidharta J Dingemanse 2011 Pharmacokinetics, tolerability, and safety of the dual endothelin receptor antagonist macitentan in Japanese and Caucasian healthy subjects Clin Pharmacol Ther 89 Suppl 1 83
4. O Kummer M Haschke F Hammann M Bodmer S Bruderer Y Regnault, et al. 2009 Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan Eur J Pharm Sci 38 4 384 8 19765655 10.1016/j.ejps.2009.09.005 1:CAS:528:DC%2BD1MXht1ynu7zL
5. RB Kim 2003 Organic anion-transporting polypeptide (OATP) transporter family and drug disposition Eur J Clin Invest 33 2 1 5 14641549 10.1046/j.1365-2362.33.s2.5.x
6. International Transporter Consortium 2010 Membrane transporters in drug development Nat Rev Drug Discov 9 3 215 36 10.1038/nrd3028
7. M Niemi JT Backman MF Fromm PJ Neuvonen KT Kivistö 2003 Pharmacokinetic interactions with rifampin: clinical relevance Clin Pharmacokinet 42 9 819 50 12882588 10.2165/00003088-200342090-00003 1:CAS:528:DC%2BD3sXntl2htr8%3D (Pubitemid 36995083)
8. SR Vavricka J Van Montfoort HR Ha PJ Meier K Fattinger 2002 Interactions of rifamycin SV and rifampin with organic anion uptake systems of human liver Hepatology 36 1 164 72 12085361 10.1053/jhep.2002.34133 1:CAS:528: DC%2BD38Xlslyru7c%3D (Pubitemid 34700774)
9. AM Baciewicz CR Chrisman CK Finch TH Self 2008 Update on rifampin and rifabutin drug interactions Am J Sci 335 2 126 36 (Pubitemid 351253409)
10. PN Sidharta J Atsmon J Dingemanse 2010 Investigation of the effect of ketoconazole on the pharmacokinetics of macitentan in healthy male subjects Br J Clin Pharmacol 70 730 1 Abstract
11. PLM van Giersbergen F Bodin J Dingemanse 2002 Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist Eur J Clin Pharmacol 58 4 243 5 12136369 10.1007/s00228-002-0459-0 (Pubitemid 34827852)
12. I Binet A Wallnöfer C Weber R Jones G Thiel 2000 Renal hemodynamics and pharmaco-kinetics of bosentan with and without CsA Kidney Int 57 1 224 31 10620203 10.1046/j.1523-1755.2000.00838.x 1:CAS:528:DC%2BD3cXivFOlu7g%3D (Pubitemid 30227769)
13. Novartis. Neoral, summary of product characteristics of Cs. 2009.
14. Sanofi-aventis. Rifadin, summary of product characteristics of rifampin. 2009.
15. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Draft guidance for industry, drug interaction studies-study design, data analysis, and implications for dosing and labeling. 2006.
16. PN Sidharta J Dingemanse 2008 Multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist ACT-064992 in healthy human subjects. (Abstract) J Clin Pharmacol 48 1114
17. A Treiber R Schneiter S Häuser B Stieger 2007 Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampin, and sildenafil Drug Metab Dispos 35 8 1400 07 17496208 10.1124/dmd.106.013615 1:CAS:528:DC%2BD2sXosVKquro%3D (Pubitemid 47121782)
18. Actelion Pharmaceuticals Ltd. Tracleer (bosentan) tablets. United States Food and Drug Administration Drug Product Label 2009.
19. R Spence A Mandagere DB Richards MH Magee C Dufton R Boinpally 2010 Potential for pharmacokinetic interactions between ambrisentan and cyclosporine Clin Pharmacol Ther 88 4 513 20 20811346 10.1038/clpt.2010.120 1:CAS:528:DC%2BC3cXhtFyjurnO
20. V Kon M Sugiura T Inagami BR Harvie I Ichikawa RL Hoover 1990 Role of endothelin in cyclosporine-induced glomerular dysfunction Kidney Int 37 6 1487 91 2194067 10.1038/ki.1990.139 1:CAS:528:DyaK3cXksFejtLc%3D (Pubitemid 20198030)
21. N Perico J Dadan G Remuzzi 1990 Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat J Am Soc Nephrol 1 1 76 83 2104254 1:CAS:528:DyaK3MXkvVCqurg%3D
22. A Fogo SE Hellings T Inagami V Kon 1992 Endothelin receptor antagonism is protective in in-vivo acute cyclosporine toxicity Kidney Int 42 3 770 4 1405355 10.1038/ki.1992.346 1:CAS:528:DyaK38XmtVCktbk%3D
23. PLM van Giersbergen A Treiber R Schneiter H Dietrich J Dingemanse 2007 Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects Clin Pharmacol Ther 81 3 414 9 17251982 10.1038/sj.clpt.6100075 (Pubitemid 46364484)
24. B Harrison MH Magee A Mandagere G Walker C Dufton LS Henderson R Boinpally 2010 Effects of rifampin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study Clin Drug Investig 30 12 875 85 20923245 10.2165/11539110-000000000-00000 1:CAS:528:DC%2BC3cXhsFaitbrK
25. H Xiong RA Carr CS Locke DA Katz R Achari TT Doan, et al. 2007 Dual effects of rifampin on the pharmacokinetics of atrasentan J Clin Pharmacol 47 4 423 9 17389551 10.1177/0091270007299928 1:CAS:528:DC%2BD2sXkvVOlu78%3D (Pubitemid 46465965)
26. HX Zheng Y Huang LA Frassetto LZ Benet 2009 Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite Clin Pharmacol Ther 85 1 78 85 18843263 10.1038/clpt.2008.186 1:CAS:528:DC%2BD1cXhsFSmtrfJ
27. Bruderer S, Hopfgartner G, Seiberling M, Wank J, Sidharta P, Treiber A, Dingemanse J. Allschwil: Actelion Pharmaceuticals Ltd. 2011. (Data on file)
28. US Food and Drug Administration. Guidance for industry 2008, safety testing of drug metabolites. US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). February 2008. Pharmacology and Toxicology.
29. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry M3(R2) 2010, nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. 2010 (Revision 1).